S26948CAS# 353280-43-0 |
- Sodium Channel inhibitor 1
Catalog No.:BCC1959
CAS No.:1198117-23-5
- Nav1.7 inhibitor
Catalog No.:BCC4191
CAS No.:1355631-24-1
- Riluzole
Catalog No.:BCC3849
CAS No.:1744-22-5
- Flecainide acetate
Catalog No.:BCC1578
CAS No.:54143-56-5
- Dibucaine (Cinchocaine) HCl
Catalog No.:BCC3760
CAS No.:61-12-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 353280-43-0 | SDF | Download SDF |
PubChem ID | 9958279 | Appearance | Powder |
Formula | C28H25NO7S | M.Wt | 519.57 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in DMSO | ||
Chemical Name | dimethyl 2-[[4-[2-(6-benzoyl-2-oxo-1,3-benzothiazol-3-yl)ethoxy]phenyl]methyl]propanedioate | ||
SMILES | COC(=O)C(CC1=CC=C(C=C1)OCCN2C3=C(C=C(C=C3)C(=O)C4=CC=CC=C4)SC2=O)C(=O)OC | ||
Standard InChIKey | NSMJEHGOMXSLCW-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C28H25NO7S/c1-34-26(31)22(27(32)35-2)16-18-8-11-21(12-9-18)36-15-14-29-23-13-10-20(17-24(23)37-28(29)33)25(30)19-6-4-3-5-7-19/h3-13,17,22H,14-16H2,1-2H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Selective PPARγ agonist (EC50 = 8.83 nM). Drives normal adipocyte differentiation and exhibits a lipid-lowering effect; reduces atherosclerosis in E2-KI mice. Displays antidiabetic properties and improves hepatic insulin sensitivity in intralipid-infusion (IL) rats. |
S26948 Dilution Calculator
S26948 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.9247 mL | 9.6233 mL | 19.2467 mL | 38.4934 mL | 48.1167 mL |
5 mM | 0.3849 mL | 1.9247 mL | 3.8493 mL | 7.6987 mL | 9.6233 mL |
10 mM | 0.1925 mL | 0.9623 mL | 1.9247 mL | 3.8493 mL | 4.8117 mL |
50 mM | 0.0385 mL | 0.1925 mL | 0.3849 mL | 0.7699 mL | 0.9623 mL |
100 mM | 0.0192 mL | 0.0962 mL | 0.1925 mL | 0.3849 mL | 0.4812 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- NS 6180
Catalog No.:BCC6307
CAS No.:353262-04-1
- LY 487379 hydrochloride
Catalog No.:BCC7627
CAS No.:353229-59-1
- D-Alaninol
Catalog No.:BCC2728
CAS No.:35320-23-1
- (E)-3-Hydroxy-5-methoxystilbene
Catalog No.:BCN5292
CAS No.:35302-70-6
- Ziyuglycoside II
Catalog No.:BCN5291
CAS No.:35286-59-0
- Ziyuglycoside I
Catalog No.:BCN5290
CAS No.:35286-58-9
- 1-Chloroindan
Catalog No.:BCN2244
CAS No.:35275-62-8
- Caesalmin B
Catalog No.:BCN7252
CAS No.:352658-23-2
- Delafloxacin meglumine
Catalog No.:BCC1523
CAS No.:352458-37-8
- 9-Methoxy-alpha-lapachone
Catalog No.:BCN5289
CAS No.:35241-80-6
- Benzoin methyl ether
Catalog No.:BCC8857
CAS No.:3524-62-7
- 4-(Bromomethyl)-7-methoxy coumarin
Catalog No.:BCC9202
CAS No.:35231-44-8
- Monocrotaline N-oxide
Catalog No.:BCN2097
CAS No.:35337-98-5
- TQS
Catalog No.:BCC7896
CAS No.:353483-92-8
- 9-Hydroxycalabaxanthone
Catalog No.:BCN5293
CAS No.:35349-68-9
- HLM006474
Catalog No.:BCC5403
CAS No.:353519-63-8
- Honokiol
Catalog No.:BCN1001
CAS No.:35354-74-6
- J 113863
Catalog No.:BCC7422
CAS No.:353791-85-2
- Norathyriol
Catalog No.:BCN5294
CAS No.:3542-72-1
- 1-Methyl-5-nitro-1H-benzimidazole-2-butanoic acid ethyl ester
Catalog No.:BCC8470
CAS No.:3543-72-4
- 1-Methyl-5-amino-1H-benzimidazole-2-butanoic acid ethyl ester
Catalog No.:BCC8469
CAS No.:3543-73-5
- 5-[Bis(2-hydroxyethyl)amino]-1-methyl-1H-benzimidazole-2-butanoic acid ethyl ester
Catalog No.:BCC8724
CAS No.:3543-74-6
- Bendamustine HCl
Catalog No.:BCC1153
CAS No.:3543-75-7
- INO-1001
Catalog No.:BCC2212
CAS No.:3544-24-9
S26948, a new specific peroxisome proliferator activated receptor gamma modulator improved in vivo hepatic insulin sensitivity in 48 h lipid infused rats.[Pubmed:19250932]
Eur J Pharmacol. 2009 Apr 17;608(1-3):104-11.
We examined whether S26948, a new specific peroxisome proliferator activated receptor gamma modulator prevented insulin-resistance induced by a 48 h intralipid-infusion in normal rat (IL rats). The effect of S26948 (30 mg/kg) was compared to rosiglitazone (10 mg/kg). Rats were catheterized in the right jugular vein 4 days before the beginning of the 48 h lipid or saline infusions. Animals were intraperitoneally injected once daily with vehicle, S26948 or rosiglitazone. At the end of the infusion the rats underwent either a glucose tolerance test or a euglycemic-hyperinsulinemic clamp. Finally isolation and incubation of hepatocytes in another series of rats were performed. Intralipid infusion leads to a 4-fold increase in plasma free fatty acid concentration compared to controls (C). Both S26948 and rosiglitazone decreased plasma free fatty acid concentration in IL rats compared to vehicle treated IL rats. Glucose-induced insulin secretion was significantly increased in IL compared to C and was associated with insulin resistance. Both S26948 and rosiglitazone treatments normalized glucose-induced insulin secretion and improved insulin action in IL rats. However, S26948 specifically improved hepatic insulin sensitivity whereas rosiglitazone improved both hepatic insulin sensitivity and insulin-stimulated glucose utilization. Finally, studies on isolated hepatocytes showed differential effect of both compounds on gene expression of key enzymes of glucose metabolism. Our data show that non thiazolidinedione S26948 may represent an alternative way for the management of dysregulated hepatic insulin sensitivity.
S 26948: a new specific peroxisome proliferator activated receptor gamma modulator with potent antidiabetes and antiatherogenic effects.[Pubmed:17704298]
Diabetes. 2007 Nov;56(11):2797-808.
OBJECTIVE: Rosiglitazone displays powerful antidiabetes benefits but is associated with increased body weight and adipogenesis. Keeping in mind the concept of selective peroxisome proliferator-activated receptor (PPAR)gamma modulator, the aim of this study was to characterize the properties of a new PPARgamma ligand, S 26948, with special attention in body-weight gain. RESEARCH DESIGN AND METHODS: We used transient transfection and binding assays to characterized the binding characteristics of S 26948 and GST pull-down experiments to investigate its pattern of coactivator recruitment compared with rosiglitazone. We also assessed its adipogenic capacity in vitro using the 3T3-F442A cell line and its in vivo effects in ob/ob mice (for antidiabetes and antiobesity properties), as well as the homozygous human apolipoprotein E2 knocking mice (E2-KI) (for antiatherogenic capacity). RESULTS: S 26948 displayed pharmacological features of a high selective ligand for PPARgamma with low potency in promoting adipocyte differentiation. It also displayed a different coactivator recruitment profile compared with rosiglitazone, being unable to recruit DRIP205 or PPARgamma coactivator-1 alpha. In vivo experiments showed that S 26948 was as efficient in ameliorating glucose and lipid homeostasis as rosiglitazone, but it did not increase body and white adipose tissue weights and improved lipid oxidation in liver. In addition, S 26948 represented one of the few molecules of the PPARgamma ligand class able to decrease atherosclerotic lesions. CONCLUSIONS: These findings establish S 26948 as a selective PPARgamma ligand with distinctive coactivator recruitment and gene expression profile, reduced adipogenic effect, and improved biological responses in vivo.